Compare

AOD-9604 vs CJC-1295

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

AOD-9604

2248 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 52% · Mixed 36% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
-165
Skin appearance
-101
Appetite control
-115
Energy
-49
Mood
-86

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
-69
Headache
-21
GI discomfort
-150
Dizziness
-54
Fatigue
-87

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 10–600 mcg

10–25
3
25–50
5
50–100
14
100–200
18
200–400
9
400–600
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing12stacking30side effects18aod-96046

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 495 repeat reporters

CJC-1295

670 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 64% · Mixed 18% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
-59
Recovery
-110
Digestive comfort
-71
Skin appearance
1
Appetite control
-102

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
-143
Anxiety
-30
Flushing
-106
Headache
-3
GI discomfort
-103

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
11
0.4–0.6 mg
21
0.6–1 mg
15
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing34stacking27side effects30cjc-129528

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 147 repeat reporters

Sources (8)

Published sources linked on the AOD-9604 and CJC-1295 wiki pages.

  1. PubMed

    A synthetic fragment of human growth hormone promotes lipid mobilization

    Heffernan MA, Thorburn AW, Fam B, et al. Int J Obes Relat Metab Disord. 2001

    Source
    Wiki study page →
  2. PubMed

    A synthetic human growth hormone fragment enhances proteoglycan synthesis

    Ng FM, Sun J, Sharma L, et al. Osteoarthritis Cartilage. 2010

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    AOD9604 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

    Heffernan MA, Thorburn AW, Fam B, et al. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001

    Source
    Wiki study page →
  5. PubMed

    The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

    Heffernan M, Summers RJ, Thorburn A, et al. Endocrinology. 2001

    Source
    Wiki study page →
  6. PubMed

    Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295

    Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006

    Source
    Wiki study page →
  7. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    CJC-1295 growth hormone studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →